AKT1 and neoplasm: In esophageal squamous cell carcinoma (ESCC) models, the PI3Kα-selective inhibitor CYH33 combined with radiotherapy suppressed PI3K/AKT signaling, reduced the phosphorylation of p-AKT and Forkhead Box O1 (FOXO1), delayed DSB repair, induced G2/M cell cycle arrest, and enhanced apoptosis while improving the tumor immune microenvironment [49].